During a pathology seminar, a faculty member discusses the immunopathology of tuberculosis infection. All of the following statements about the immune response in TB are correct EXCEPT:

Explanation

## Immunopathology of Tuberculosis **Key Point:** TB is fundamentally a **cell-mediated (Type IV hypersensitivity) disease**. Antibodies play a minor role in protection; the primary defense is **Th1-mediated cellular immunity**. ### Immune Response Hierarchy in TB ```mermaid flowchart TD A["M. tuberculosis infection"]:::outcome --> B["Intracellular pathogen<br/>in macrophages"]:::outcome B --> C{"Immune response type?"}:::decision C -->|"Primary (90%)"| D["Cell-mediated immunity<br/>Type IV hypersensitivity"]:::action C -->|"Secondary (minor)"| E["Humoral immunity<br/>Antibodies"]:::action D --> F["Th1 cells activated"]:::action F --> G["IFN-γ production"]:::action G --> H["Macrophage activation"]:::action H --> I["Intracellular bacilli killed"]:::outcome E --> J["Opsonization & complement<br/>Minimal protection"]:::outcome ``` ### Components of Protective Immunity | Component | Role in TB | Effectiveness | |-----------|-----------|---------------| | **Th1 cells** | Produce IFN-γ; activate macrophages | Primary protection | | **IFN-γ** | Upregulates MHC-II, TNF-α, antimicrobial peptides | Essential for control | | **Macrophage activation** | Increased phagolysosomal fusion, ROS production | Kills intracellular bacilli | | **CD8+ T cells** | Cytotoxic; kill infected cells | Important in advanced TB | | **Antibodies (IgG, IgA)** | Opsonization, complement fixation | **Minimal role** in protection | | **DTH reaction** | Granuloma formation; containment | Double-edged: protection + tissue damage | **High-Yield:** The **Mantoux test (tuberculin skin test)** is a manifestation of DTH—it demonstrates prior sensitization but does NOT correlate with protection. A positive TST can occur in both latent TB and active TB disease. ### Why Antibodies Are NOT Protective 1. **Intracellular location:** M. tuberculosis lives inside macrophages, shielded from circulating antibodies. 2. **Antigenic variation:** TB bacilli express variable surface antigens, limiting antibody recognition. 3. **Clinical evidence:** Patients with severe B-cell deficiency (e.g., X-linked agammaglobulinemia) control TB reasonably well; those with T-cell deficiency (e.g., HIV/AIDS) develop disseminated TB. 4. **Vaccine data:** BCG protection correlates with Th1 response, not antibody titers. **Clinical Pearl:** HIV-positive patients with CD4 count <50 cells/μL have a 500-fold increased risk of TB reactivation because Th1 cells are depleted. This underscores the primacy of cell-mediated immunity. **Warning:** Do not confuse "antibodies are present in TB" (true) with "antibodies protect against TB" (false). Serology for TB (anti-TB IgG) has poor sensitivity and specificity and is NOT recommended for diagnosis.